"We have read for you"Cimicifuga: an ally for women.
The extracts of Cimicifuga racemosa are used throughout the world to counteract the symptoms of menopause.
I have read for you a German study in which some researchers did a review of the literature produced over sixty years on Cimicifuga racemosa to alleviate the symptoms of menopause. Cimicifuga is available in Germany since the 1950s. A long period of time to assess its safety and efficacy through several clinical studies.
Cimicifuga or Actea Racemosa is a native plant of the United States of America, belonging to the Ranuncolaceae family, which grows in a humid environment. It comes with small white flowers and large leaves, but the most used part is underground (called rhizome). This plant extracts are rich in phytoestrogens, natural substances with a similar action to that of estrogen. For this reason, it is one of the best known natural remedies to counteract menopause manifestations, beeing effective with hot flashes, mood disorders and vaginal dryness. It also has the ability to act on the nervous system as a sedative and has hypotensive action.
The name comes from the Latin cimix which means cimice and fugus, that is to say, "to make run away". It was believed that Cimicifuga, with the particular smell of its flowers, could eliminate insects.
The first studies on this plant use in the 1950s and 1960s in Germany and Europe were observational. In the 1980s, controlled studies began. The first controlled study was carried out in 1986 with the administration of Cimicifuga extract to a group and placebo to the other.
From 2000 to 2015, however, the studies published in Europe, Asia and America on this herbal medicine are 28.
The total number of patients who took extracts of Cimicifuga racemosa is 11,073. 93% of these took isopropanol extract. As early as 2013, a meta-analysis of all placebo-controlled studies until that year was carried out, which confirmed the efficacy of Cimicifuga to mitigate and resolve the symptoms of menopause (redness, vaginal dryness, sweating, loss of libido).
The safety of Cimicifuga extracts has been demonstrated during decades of preclinical and clinical studies. This made it possible to document its efficacy in the management of menopausal and premenopausal patients symptoms.
The review shows that, in addition to the already known positive effects, it has additional beneficial effects such as the delay of a new onset of the disease after breast cancer. Other effects include thermoregulation, mood, sleep cycle regulation, osteoporosis prevention and uterine fibroids reduction.
The researchers concluded that plant extracts meet the regulatory requirements for long-term treatments and are safe for estrogen-sensitive tissues such as sinuses, uterus and tumors. Taking this active ingredient did not alter the action of aromatase inhibitors or tamoxifen and did not show hepatotoxicity.
Cimicifuga differs from soy isoflavones, very known phytoestrogens, due to the absence of similar estrogenic effects (that is to say, it does not alter estrogen production and regulation). This characteristic makes its use possible even in women with familiarity or a history of breast cancer who are advised not to use natural or synthetic hormones.
There are several products on the market that contain Cimicifuga. Those ones, if combined with the right natural ingredients that improve their characteristics, creating the right synergy, are a valid and safe aid for different gynecological conditions.
The most suitable active ingredients to associate with Cimicifuga are Morinda Citrifolia, Melissa Officinalis, Escholtzia Californica, Zingiber Officinale and Angelica Sinensis. This combination can be found in Adolci food supplement that helps to counteract menstrual cycle and menopause disorders by having antispasmodic and muscle relaxing action to help premenstrual muscle tension and other painful symptoms relief; it regulates sleep cycle, helps gastrointestinal motility and limits gas formation.
Henneicke-von Zepelin HH. 60 years of Cimicifuga racemosa medicinal products: Clinical research milestones, current study findings and current development. Wien Med Wochenschr. 2017;167(7-8):147-159.
Obstetrician Sara Furno